Preparation of novel Azo Dyes as a new anti-Human Breast Cancer MDAMB231 Cells and study its association with DNA

Abstract EN

The 4,6-bis((E)-(3-nitrophenyl)diazenyl) benzene-1,3-diol (1), 4-((E)-(3- nitrophenyl)diazenyl)-6-((E)-(4-nitrophenyl)diazenyl)benzene -1,3-diol (2), 4-((E)-(2- nitrophenyl) diazenyl)-6-((E)-(3-nitrophenyl)diazenyl)benzene-1,3-diol (3), 4,6-bis((E)-(2- nitrophenyl) diazenyl)benzene-1,3-diol (4), (N-(4-hydroxy-3-(((4-(5-(p-tolyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonyl)diazenyl)phenyl)acetamide (5), 3- (isopropylamino)-1-(4-(2-methoxyethyl)phenoxy)-1-((3-nitrophenyl)diazenyl)propan-2-ol (6), 3-(isopropylamino)-1-(4-(2-methoxyethyl)phenoxy)-1-((2-nitrophenyl)diazenyl)propan- 2-ol (7) and 4-(((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonyl) diazenyl)benzene-1,3-diol (8) were synthesised.

The resulting diazo dyes and pharmaceutical azo dyes were characterized by IR, UV-visible, mass spectrum and 1H NMR spectrum respectively.

All the synthetic azo dyes were provided non-toxic effects, and didn't show any hemolysis effect in the blood cells.

The azo compounds were reduced human breast MDAMB231 cancer cells growth, after 24h treatment with 100μM.

Further, the results of human DNA binding of each azo dye were indicated its ability to damage DNA.

Due to recommend the synthetic, non-toxic azo dyes as novel drugs for treatment of human breast MDA-MB231 cancer cells through its ability to destroy the DNA of the cancer cells.